Table 4 Selected ongoing/completed clinical trials involving tumor-derived systems (Source: https://clinicaltrials.gov/)
From: Tumor-derived systems as novel biomedical tools—turning the enemy into an ally
System | NCT Number | Status | Overview of Study |
|---|---|---|---|
EVs | NCT05270174 | Not yet recruiting | Evaluation and validation of exosomal long noncoding RNA ELNAT1 as an independent predictor of lymph node metastasis in bladder cancer |
NCT04556916 | Recruiting | Investigation of circulating blood-based biomarkers (including tumor-derived exosomes) for early detection of prostate cancer | |
NCT04394572 | Completed | Investigation of protein markers transported by tumor exosomes for noninvasive colorectal cancer diagnostic | |
NCT02507583 | Completed | The study explored immunotherapy of malignant glioma using exosomes derived from patient-derived cancer cells after treatment with an investigational antisense molecule | |
NCT05286684 | Recruiting | Investigation of cerebrospinal fluid microvesicles using a high-throughput clinical proteomic approach for improved profiling of metastatic tumor meningitis | |
NCT01344109 | Withdrawn | The study assessed the use of tumor-derived exosomes as a marker for response to therapy in women receiving neoadjuvant chemotherapy for newly diagnosed breast cancer | |
NCT05397548 | Recruiting | Investigation of circulating exosomal long noncoding RNA GC1 as a potential biomarker for the detection of gastric cancer | |
NCT05463107 | Not yet recruiting | Investigation of a potential correlation between exosomal protein biomarkers and pathological manifestation in thyroid follicular neoplasm | |
NCT03334708 | Recruiting | Development of a minimally invasive test for early diagnosis and treatment response monitoring in pancreatic cancer using blood-based biomarkers (including tumor-associated exosomes) | |
NCT03236675 | Active, not recruiting | Investigated the potential of detecting patient-specific gene rearrangement/mutation from circulating exosomes in patients of non-small cell lung cancer | |
TCL | NCT01635283 | Completed | Evaluation of safety and efficacy on survival of patients with low-grade glioma, treated with autologous DCs pulsed with autologous TCL |
NCT02215837 | Active, not recruiting | Evaluation of safety and efficacy of chemotherapy combined with autologous TCL-pulsed DCs for gastric cancer | |
NCT00405327 | Completed | Study of TCL as a vaccine for high-risk solid tumor patients following stem cell transplantation | |
NCT03114631 | Completed | Evaluation of safety and efficacy of novel peptide combined with TCL-pulsed DCs as immunotherapy in pancreatic cancer | |
NCT01204684 | Active, not recruiting | Evaluation of safety and efficacy of immunotherapy using autologous tumor lysate-pulsed DCs in patients with an intracranial brain tumor | |
NCT02678741 | Completed | Safety and tumor response assessment of autologous TCL, yeast cell wall particles, and DCs vaccine with checkpoint inhibitors in stage IV melanoma | |
NCT01678352 | Completed | Evaluation of a novel vaccination regime comprised of TCL and imiquimod (an FDA-approved immune response modifier) in glioma patients | |
NCT03360708 | Active, not recruiting | Evaluation of safety and feasibility of malignant glioma TCL-pulsed autologous DCs vaccine in glioblastoma patients at first or second recurrence | |
NCT03395587 | Recruiting | Evaluating the efficacy of integrating vaccination with TCL-loaded mature DCs into standard radio/chemotherapy for newly diagnosed glioblastoma patients | |
Tumor Organoids | NCT05842187 | Recruiting | Evaluation of the consistency between in vitro tumor organoid drug sensitivity and the therapeutic efficacy of in vivo drug treatment in patients with metastatic pancreatic or gastric cancer |
NCT04777604 | Not yet recruiting | Evaluation of patient-derived organoids as predictive platforms to select appropriate neoadjuvant chemotherapy before surgery, based on unique genomic mutations | |
NCT05203549 | Recruiting | Assessment of the consistency between treatment responses in patient-derived organoids and actual clinical outcomes in 250 gastric cancer patients | |
NCT05304741 | Recruiting | The study aims to establish organoid-based platforms that represent different types (advanced/recurrent/metastatic) of colorectal cancer patients and apply them to drug screening | |
NCT05007379 | Not yet recruiting | Development and evaluation of patient-derived breast cancer organoids to test the antitumor activity of novel chimeric antigen receptor-macrophages | |
NCT04342286 | Completed | Development of a reproducible organoid culture model using human kidney cells and their evaluation for developing personalized/targeted therapy | |
NCT05669586 | Recruiting | Evaluation of the consistency and accuracy of patient-derived lung cancer organoids, to select personalized treatment regiments for patients with resistance to multiline standard therapies | |
NCT04865315 | Active, not recruiting | Development of patient-derived organoids of high-grade and low-grade gliomas and their utilization in identifying underlying mechanisms that contribute to malignancy and treatment resistance | |
NCT04826913 | Not yet recruiting | Evaluation of a high throughput device based on 3D nanomatrices and 3D tumors with functional vascularization for personalized drug screening | |
NCT05196334 | Recruiting | Investigation of pancreatic ductal adenocarcinoma organoids cocultured with CAFs for pharmacotyping using relevant chemotherapeutic agents used in the clinic |